Triptorelin is a synthetic decapeptide hormone which falls under the gonadotropin-releasing hormone agonist (GnRH agonist) utilized as the pamoates or acetate salts. GnRH is Triptorelin (GnRH) initiates persistent stimulation of the pituitary glands and therefore leads to a decline in the levels of follicle stimulating hormone (FSH) and gonatropins luteinizing hormone (LH) secreted by the pituitary gland. It achieves this function by over stimulating the body’s production of these hormones hence leading to a temporary shutdown of their production. Similar to other GnRH agonists, it can be utilized in therapy against hormone-responsive cancers that include breast cancer or prostate cancer, estrogen-dependent …show more content…
As such, all findings and observations made on the mechanism, functionality, or theoretical benefits of triptorelin should be strictly confined to controlled environments that include a laboratory or a medical research facility.
In animal based studies, researchers observed that triptorelin’s main function is to minimize the expression of follicle stimulating hormone (FSH) and luteinizing hormone (LH). LH is the hormone that controls the production of estrogen in female animal subjects while in male animal subjects it controls the production of testosterone. FSH plays a key role in the regulation of growth, development, and maturation during puberty in both the male and female animal test subjects. Triptorelin is said to offer better regulatory process of developmental hormone secretion and consequently enabling an enhanced measure of homeostasis as it is linked to growth and …show more content…
The researchers sought to determine the variation in hormonal profile and side effects as a result of hypoestrogenic status following treatment with leuprorelin and triptorelin in Chinese women who had undergone conservative surgical treatment and had ovarian endometrioma. This particular study employed 302 women who had laparoscopic excision of ovarian endometriomas performed with rASRM III and IV. The women were then randomly allocated into two groups but 22 patients dropped out of the study. The 142 study subjects in group A were intravenously administered with 3 doses of leuprorelin while the138 study subjects in group B were intravenously administered with triptorelin in intervals of 4 weeks post surgical therapy. The researchers then utilized questionnaires to evaluate menopausal symptoms and they also measured the levels of serum sex hormonal levels. Results obtained at the end of week 4 of treatment indicated that majority of the patients in group A (leuprorelin) did not exhibit any obvious side effects. Patients in both groups had similar side effects after 9 weeks of treatment, with the major side effects observed including sweating, hot flashes, bone pain, and irregular bleeding. Group B (triptorelin) showed higher levels of depression, anxiety,